Feasibility randomised controlled trial of the Early Adolescent Skills for Emotions psychological intervention with young adolescents in Lebanon.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 24 08 2022
accepted: 27 01 2023
entrez: 1 3 2023
pubmed: 2 3 2023
medline: 4 3 2023
Statut: epublish

Résumé

Globally, there is a vast mental health treatment gap, whereby the majority of adolescents living in low- and middle-income countries requiring mental health services, do not have access to adequate care. To improve access, the World Health Organization (WHO) developed a range of interventions, designed to be low-cost and delivered by non-specialists. We conducted a two-arm, individually randomised group treatment feasibility trial of a new WHO group intervention for young adolescents with emotional distress ('Early Adolescent Skills for Emotions'; EASE) in Lebanon. The aim of this study was to determine the feasibility of the intervention and study procedures. Adolescents aged 10 to 14 years were eligible to take part if they scored above a validated cut-off on the Child Psychosocial Distress Screener. Participants were randomized to EASE or enhanced treatment as usual (ETAU) control using a 1:1 ratio. EASE consisted of seven group sessions with adolescents and three sessions with caregivers. ETAU consisted of a single brief psychoeducation home visit. Child and caregiver outcomes were measured by blind assessors at baseline, endline (8 weeks post-randomisation), and three month follow-up (20 weeks post-randomisation), with the primary outcome measure being child psychological symptoms on the Pediatric Symptom Checklist. Qualitative interviews were conducted with adolescents (n = 13), caregivers (n = 17), facilitators (n = 6), trainers (n = 3), and outreach staff (n = 1) at endline to assess barriers and facilitators related to the feasibility and delivery of EASE and study procedures. Of 154 adolescents screened, 67 (43%) were eligible, completed baseline, and were randomized. Sixty adolescents (90%) completed endline assessments (31 EASE, 29 ETAU), and fifty-nine (88%) completed three-month assessments (29 EASE, 30 ETAU). Qualitatively, participants provided overall positive feedback about the intervention. Several challenges and suggestions for improvement were raised around logistics, intervention content, and acceptability of assessment measures. Implementation data highlighted challenges with intervention uptake and attendance. Outcome measures generally had strong psychometric properties (range: α = 0.77 to α = 87), however did not demonstrate change over time in either group. The EASE intervention and study procedures are acceptable and feasible for implementation with vulnerable adolescents in Lebanon, however several improvements are necessary prior to full-scale evaluation. #ISRCTN60799626, retrospectively registered on 04/10/2022.

Sections du résumé

BACKGROUND
Globally, there is a vast mental health treatment gap, whereby the majority of adolescents living in low- and middle-income countries requiring mental health services, do not have access to adequate care. To improve access, the World Health Organization (WHO) developed a range of interventions, designed to be low-cost and delivered by non-specialists. We conducted a two-arm, individually randomised group treatment feasibility trial of a new WHO group intervention for young adolescents with emotional distress ('Early Adolescent Skills for Emotions'; EASE) in Lebanon.
METHOD
The aim of this study was to determine the feasibility of the intervention and study procedures. Adolescents aged 10 to 14 years were eligible to take part if they scored above a validated cut-off on the Child Psychosocial Distress Screener. Participants were randomized to EASE or enhanced treatment as usual (ETAU) control using a 1:1 ratio. EASE consisted of seven group sessions with adolescents and three sessions with caregivers. ETAU consisted of a single brief psychoeducation home visit. Child and caregiver outcomes were measured by blind assessors at baseline, endline (8 weeks post-randomisation), and three month follow-up (20 weeks post-randomisation), with the primary outcome measure being child psychological symptoms on the Pediatric Symptom Checklist. Qualitative interviews were conducted with adolescents (n = 13), caregivers (n = 17), facilitators (n = 6), trainers (n = 3), and outreach staff (n = 1) at endline to assess barriers and facilitators related to the feasibility and delivery of EASE and study procedures.
RESULTS
Of 154 adolescents screened, 67 (43%) were eligible, completed baseline, and were randomized. Sixty adolescents (90%) completed endline assessments (31 EASE, 29 ETAU), and fifty-nine (88%) completed three-month assessments (29 EASE, 30 ETAU). Qualitatively, participants provided overall positive feedback about the intervention. Several challenges and suggestions for improvement were raised around logistics, intervention content, and acceptability of assessment measures. Implementation data highlighted challenges with intervention uptake and attendance. Outcome measures generally had strong psychometric properties (range: α = 0.77 to α = 87), however did not demonstrate change over time in either group.
CONCLUSIONS
The EASE intervention and study procedures are acceptable and feasible for implementation with vulnerable adolescents in Lebanon, however several improvements are necessary prior to full-scale evaluation.
TRIAL REGISTRATION
#ISRCTN60799626, retrospectively registered on 04/10/2022.

Identifiants

pubmed: 36858980
doi: 10.1186/s12888-023-04571-9
pii: 10.1186/s12888-023-04571-9
pmc: PMC9979451
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

131

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Investigateurs

Katie S Dawson (KS)
Sarah Watts (S)
Maha Ghatasheh (M)
May Aoun (M)
Aiysha Malik (A)
Felicity L Brown (FL)
Ceren Acarturk (C)
Aemal Akhtar (A)
Ibrahim Akinçi (I)
Ahmed Bawaneh (A)
Martha Bird (M)
Felicity L Brown (FL)
Richard Bryant (R)
Sebastian Burchert (S)
Pim Cuijpers (P)
Anne de Graaff (A)
Annelieke Drogendijk (A)
Daniela Fuhr (D)
Jonas Maria Hessling (JM)
Zeynep Ilkkursun (Z)
Mark J D Jordans (MJD)
Christine Knaevelsrud (C)
Gülşah Kurt (G)
David McDaid (D)
Saara Martinmäki (S)
Cansu Mirzanlı (C)
Trudy Mooren (T)
Naser Morina (N)
A-La Park (AL)
Monique Pfaltz (M)
Bayard Roberts (B)
Matthis Schick (M)
Ulrich Schnyder (U)
Marit Sijbrandij (M)
Egbert Sondorp (E)
Julia Spaaij (J)
Frederik Steen (F)
Karine Taha (K)
Peter Ventevogel (P)
Claire Whitney (C)
Nana Wiedemann (N)
Aniek Woodward (A)

Informations de copyright

© 2023. The Author(s).

Références

BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Behav Res Ther. 2021 Oct;145:103944
pubmed: 34392115
Behav Res Ther. 2015 Jun;69:11-21
pubmed: 25847276
PLoS Med. 2017 Aug 15;14(8):e1002371
pubmed: 28809935
PLoS Med. 2021 Jun 17;18(6):e1003621
pubmed: 34138875
World Psychiatry. 2019 Feb;18(1):105-107
pubmed: 30600639
PLoS Med. 2022 Aug 12;19(8):e1004046
pubmed: 35960704
Pediatrics. 2010 Dec;126(6):1117-23
pubmed: 21041282
Soc Psychiatry Psychiatr Epidemiol. 2002 Nov;37(11):537-43
pubmed: 12395144
Eur J Psychotraumatol. 2021 Nov 29;12(1):1901408
pubmed: 34868475
Lancet. 2018 Oct 27;392(10157):1553-1598
pubmed: 30314863
J Child Psychol Psychiatry. 2017 Apr;58(4):507-524
pubmed: 27943284
Lancet. 2019 Apr 27;393(10182):1733-1744
pubmed: 30948286
JAMA. 2016 Dec 27;316(24):2609-2617
pubmed: 27837602
Trials. 2019 Sep 2;20(1):545
pubmed: 31477178
Epidemiol Psychiatr Sci. 2013 Sep;22(3):197-203
pubmed: 23941725
Lancet Psychiatry. 2020 Feb;7(2):162-172
pubmed: 31948935
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Glob Health. 2017 Dec;7(2):020901
pubmed: 29302326
Br J Psychiatry. 2017 Feb;210(2):119-124
pubmed: 27908899
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
J Am Acad Child Adolesc Psychiatry. 2021 Jun;60(6):667-668
pubmed: 33188854
Lancet. 2019 Jul 20;394(10194):240-248
pubmed: 31200992
PLoS Med. 2018 Mar 9;15(3):e1002524
pubmed: 29522518
Eur Child Adolesc Psychiatry. 2019 Oct;28(10):1295-1310
pubmed: 30151800
J Epidemiol Community Health. 1995 Aug;49(4):431-6
pubmed: 7650469
Psychol Assess. 2016 May;28(5):613-625
pubmed: 26348028
Lancet Glob Health. 2018 Apr;6(4):e390-e400
pubmed: 29530422
Front Psychiatry. 2020 Mar 23;11:212
pubmed: 32265759
Am J Orthopsychiatry. 2008 Jul;78(3):290-9
pubmed: 19123748
Child Adolesc Psychiatry Ment Health. 2022 Jun 21;16(1):47
pubmed: 35729589

Auteurs

Felicity L Brown (FL)

Research and Development Department, War Child Holland, Amsterdam, The Netherlands. felicity.brown@warchild.nl.
Amsterdam Institute of Social Science Research, University of Amsterdam, Amsterdam, the Netherlands. felicity.brown@warchild.nl.

Karine Taha (K)

Research and Development Department, War Child Holland, Amsterdam, The Netherlands.
War Child Lebanon, Beirut, Lebanon.

Frederik Steen (F)

Research and Development Department, War Child Holland, Amsterdam, The Netherlands.

Jeremy Kane (J)

Mailman School of Public Health, Columbia University, New York, USA.

Aviva Gillman (A)

Kings College London, London, UK.

May Aoun (M)

Research and Development Department, War Child Holland, Amsterdam, The Netherlands.
War Child Lebanon, Beirut, Lebanon.

Aiysha Malik (A)

Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.

Richard Bryant (R)

School of Psychology, University of New South Wales, Sydney, NSW, Australia.

Marit Sijbrandij (M)

Clinical, Neuro and Developmental Psychology, VU University, Amsterdam, The Netherlands.

Rabih El Chammay (R)

Ministry of Public Health, Beirut, Lebanon.
Department of Psychiatry, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Chiara Servili (C)

Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.

Mark van Ommeren (M)

Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.

Aemal Akhtar (A)

School of Psychology, University of New South Wales, Sydney, NSW, Australia.
Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Edwina Zoghbi (E)

World Health Organization, Beirut, Lebanon.

Mark J D Jordans (MJD)

Research and Development Department, War Child Holland, Amsterdam, The Netherlands. mark.jordans@warchild.nl.
Amsterdam Institute of Social Science Research, University of Amsterdam, Amsterdam, the Netherlands. mark.jordans@warchild.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH